STOCK TITAN

Marex Group Ltd (MRX) executive sells 16,668 shares under Rule 10b5-1 plan

(Very High)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Marex Group Ltd insider Paolo Tonucci, Chief Strategist and CEO, Capital Markets, reported selling a total of 16,668 Ordinary Shares of MRX on August 10, 2026 in three open-market transactions at weighted average prices of $60.6402, $61.6184, and $62.2222 per share. These sales were effected pursuant to a Rule 10b5-1 plan entered into on October 22, 2025. A related footnote states that the number of ordinary shares reported for him includes 220,746 shares underlying deferred bonus plan awards, each representing a contingent right to receive one ordinary share upon vesting and settlement.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Tonucci Paolo
Role See Remarks
Sold 16,668 shs ($1.02M)
Type Security Shares Price Value
Sale Ordinary Shares F1, F2 12,250 $60.6402 $743K
Sale Ordinary Shares F1, F3 3,963 $61.6184 $244K
Sale Ordinary Shares F1, F4, F5 455 $62.2222 $28K
Holdings After Transaction: Ordinary Shares — 1,265,609 shares (Direct)
Footnotes (5)
  1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $60.105 to $61.1, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $61.17 to $62.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $62.16 to $62.265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5. The number of ordinary shares reported herein includes 220,746 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.
Total shares sold 16,668 shares Aggregate Ordinary Shares sold by Paolo Tonucci on August 10, 2026
First sale tranche 12,250 shares at $60.6402 Weighted average price; trades ranged from $60.105 to $61.1
Second sale tranche 3,963 shares at $61.6184 Weighted average price; trades ranged from $61.17 to $62.07
Third sale tranche 455 shares at $62.2222 Weighted average price; trades ranged from $62.16 to $62.265
Deferred bonus plan awards 220,746 shares Underlying shares included in reported holdings via deferred bonus plan awards
Rule 10b5-1 plan regulatory
"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
deferred bonus plan awards financial
"includes 220,746 shares underlying deferred bonus plan awards previously granted"
Deferred bonus plan awards are payments promised to employees or executives that are earned now but paid out later, often only if certain performance goals are met or the employee remains with the company. For investors, they matter because they influence management’s incentives and company expenses over time—like a delayed paycheck that encourages someone to stay and meet targets—and can affect future cash needs, reported compensation costs, and potential share dilution.
contingent right financial
"Each award represents a contingent right to receive one (1) ordinary share"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Marex Group Ltd (MRX) insider Paolo Tonucci report in this Form 4?

Paolo Tonucci reported selling 16,668 Ordinary Shares of Marex Group Ltd on August 10, 2026 in three open-market transactions at weighted average prices between about $60.10 and $62.27 per share, as detailed in the filing and related footnotes.

Were the MRX share sales by Paolo Tonucci under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 plan that Tonucci entered into on October 22, 2025. Such pre-arranged plans allow insiders to trade shares according to preset instructions, independent of subsequent material non-public information.

How many Marex Group Ltd (MRX) shares did Paolo Tonucci sell and at what prices?

He sold 16,668 Ordinary Shares of MRX: 12,250 shares at a weighted average price of $60.6402, 3,963 shares at $61.6184, and 455 shares at $62.2222. Footnotes explain each price is a weighted average over specified intraday trading ranges.

What trading price ranges are disclosed for the MRX insider sales on August 10, 2026?

Footnotes disclose that the weighted average prices reflect trades in ranges of $60.105–$61.1, $61.17–$62.07, and $62.16–$62.265 per share. The reporting person undertakes to provide detailed trade-by-trade pricing information to interested parties upon request.

What does the deferred bonus plan disclosure mean for MRX insider Paolo Tonucci?

A footnote explains that his reported ordinary share holdings include 220,746 shares underlying deferred bonus plan awards. Each award represents a contingent right to receive one Marex Group Ltd ordinary share upon vesting and settlement of the respective award, rather than shares currently issued from the plan.

Does the Form 4 state Paolo Tonucci’s total MRX share ownership after these sales?

The Form 4 notes that his reported holdings include 220,746 deferred bonus plan shares, but it does not provide a single consolidated figure for shares owned following the transactions. Only the amounts sold and the nature of certain included awards are specified in the disclosure.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tonucci Paolo

(Last)(First)(Middle)
C/O MAREX GROUP LIMITED, 155 BISHOPSGATE

(Street)
LONDONEC2M 3TQ

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Issuer Name and Ticker or Trading Symbol
Marex Group Ltd [ MRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares08/10/2026S(1)12,250D$60.6402(2)1,270,027D
Ordinary Shares08/10/2026S(1)3,963D$61.6184(3)1,266,064D
Ordinary Shares08/10/2026S(1)455D$62.2222(4)1,265,609(5)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $60.105 to $61.1, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $61.17 to $62.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $62.16 to $62.265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The number of ordinary shares reported herein includes 220,746 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.
Remarks:
Chief Strategist and CEO, Capital Markets
/s/ Scott Linsley as Attorney-in-Fact, for Paolo Tonucci08/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)